Adalvo Celebrates Unique European Nod For Prolonged-Release Pregabalin
Launch Imminent For ‘First Once-Daily Pregabalin Formulation’ Value Added Medicine
Adalvo, the B2B unit of the Alvo group of companies, has announced a successful decentralized European approval for its pregabalin prolonged-release tablets, with a launch imminent. The “milestone” for its value added medicines program could allow the firm to offer what it has previously billed as “the first once-daily pregabalin formulation.”
You may also be interested in...
Samsung Bioepis has celebrated becoming the first developer to obtain approvals for both Lucentis and Eylea biosimilars, after its SB15 aflibercept candidate was approved in Korea.
The Global Generics & Biosimilars Awards returns to Milan this October, recognizing the top achievements across the generics, biosimilars and value added medicines industries. Entries are now open and you can also book tickets to attend, both of which are free of charge.
‘Fast Forward Four Or Five Years, We’re Going To Look Very Different’ – Rosemont Chief Eyes ‘Transformative’ International M&A
UK-based liquids specialist Rosemont Pharmaceuticals is on the lookout for M&A opportunities, particularly as it looks to build up its business in the US, chief executive Howard Taylor tells Generics Bulletin in an exclusive interview.